Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition

Table 1

Pathologic complete response after neoadjuvant chemotherapy in patients with HER2-positive breast cancer stratified by hormonal receptor status.

Clinical trial	Chemotherapy and HER2-targeted agents	Outcome	pCR rate; HR+/HER2+	pCR rate; HR-/HER2+	Reference
NeoSphere	Docetaxel; Carboplatin; Trastuzumab	ypT0^a	20.0%	36.8%	[32]
NeoSphere	Docetaxel; Carboplatin; Trastuzumab; Pertuzumab	ypT0	26.0%	63.2%	[32]
NeoALTO	Paclitaxel; Lapatinib; Trastuzumab	ypT0	41.6%	61.3%	[33]
NOAH	Doxorubicin; Paclitaxel; Cyclophosphamide; Methotrexate; Fluorouracil; Trastuzumab	ypT0; ypN0^b	30.0%	51.2%	[12]
ACOSOG Z1041	5-fluorouracil; Epirubicin; Cyclophosphamide; Paclitaxel; Trastuzumab	ypT0	47.6%	70.4%	[34]

a–ypT0: pathologic complete response in the breast (absence of invasive neoplastic cells); b–ypN0: pathologic complete response in the axillary lymph nodes (absence of invasive neoplastic cells).